TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06006299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transauricular Vagus Nerve Stimulation
Description: Transcutaneous auricular vagus nerve stimulation (taVNS) is a form of transcutaneous electrical nerve stimulation (TENS) applied to peripheral nerves, considered a low-risk procedure. It involves the use of standard neurostimulation electrodes placed on the surface of the external ear. The taVNS method delivers low-intensity, pulsed electrical currents with a peak current amplitude of \<4 mA, which is significantly lower than those used in most over-the-counter TENS devices for pain relief or muscle stimulation. By targeting the auricular branches of the vagus nerve, taVNS aims to stimulate specific neural pathways associated with various indications and intended uses. This non-invasive approach has broad applications in research, medical device treatments, health products, and cosmetic or lifestyle products.
Study: NCT06508580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Component 1: Calorie Goal Attainment
Description: On weeks that participants are randomized to receive this component, they will be provided with feedback on the number of days that they met their calorie goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Component 2: Diet Quality
Description: On weeks that participants are randomized to receive this component, they will receive three comments regarding specific dietary choices that may impact weight loss success, including reinforcing comments for behaviors consistent with weight loss and potential areas for change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Component 3: Physical Activity Goal Attainment
Description: On weeks that participants are randomized to receive this component, they will receive feedback related to attainment of that week's physical activity goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Component 4: Goal Setting
Description: On weeks that participants are randomized to receive the goal setting component, they will be asked to complete an open-text prompt encouraging them to set a specific weight-related behavior change goal for the next week.
Study: NCT06026033

Intervention type: DRUG
Intervention: Desflurane induction
Description: Following tracheal intubation, the fresh gas flow will be set to 1 liters/minute, desflurane vaporizer will be set to maximum.
Study: NCT06186050

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot drink
Description: Drink containing 10g of beetroot powder in 250 mL cold tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mio flavouring in 250 mL cold tap water. Trace amounts of sugar and sodium were added to match the content in the beetroot supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Low-fat meal with cornflakes, greek yogurt, skim milk, and orange juice
Study: NCT06114238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab AI
Description: Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous AI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itepekimab PFS
Description: Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous PFS
Study: NCT04638231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive messages
Description: Daily supportive messages via SMS or email

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive messages
Description: Daily supportive messages via SMS or email
Study: NCT05375461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsules
Description: The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB3616-matching placebo
Description: The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvestrin injection
Description: Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvestrin injection
Description: Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
Study: NCT05998018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pdSTIM System Therapy
Description: Stimulate the phrenic nerves in synchrony with inspiratory cycles of the ventilator which exercises the diaphragm
Study: NCT05672784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GNB plus standard analgesia
Description: When patients are in supine position with a pillow under the popliteal fossa, we will target points next to superior medial, superior lateral, and inferior medial genicular arteries to block the superior medial, superior lateral, and inferior medial branches of genicular nerve. For identification, we will use color Doppler near the periosteal areas (the junctions of the epicondyle with the shafts of the femur and tibia, accordingly). using a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) positioned parallel to the shaft of the long bones in the legs, the needle will be inserted ( in plane technique in the long-axis view) and a 2.5 mL of bupivacaine (5%) will be injected at each target points.standard analgesia will be given post-operativelly (paracetamol 1 gm/ three times a daily and meloxicam (15 mg)once a day)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GNB plus IPACK block plus standard analgesia
Description: IPACK block will be done when the patients in supine position with the knee flexed in 45 degree. using a low frequency transducer at a depth of 3.5-4 cm positioned transversely, 2-3 cm above the patella and over the medial aspect of the knee, we will identify the distal part of the shaft of the femur and the popliteal artery with sliding the transducer proximally and distally (If the two femoral condyles appear first, proximal sliding of the probe, so the humps of the femoral condyles will disappeared and the flat metaphysis will appeared). With advancement of the needle in plane toward the space between the popliteal artery and the femur, 15 ml of bupivacaine 0.5% will be injected. The genicular nerve block will be done as in group G and standard analgesia will be given post-operative as in group G

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard analgesia (paracetamol and meloxicam)
Description: (paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard analgesia (paracetamol and meloxicam)
Description: (paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard analgesia (paracetamol and meloxicam)
Description: (paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.
Study: NCT04889105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smart MOVE!
Description: Multi-component behavioral intervention of PAD consisting of:~1. guideline-directed HBET prescription~2. active behavioral coaching (via MOVE! program or other)~3. mobile health monitoring

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General walking advice
Description: Basic guidance on performing walking exercises for PAD according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Performance evaluation
Description: Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include:~1. Provider and stakeholder interviews~2. PAD patient interviews~2) N-of-1 trials to refine the intervention
Study: NCT06441500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily tooth brushing programme
Description: Implementing the toothpaste/toothbrushing scheme involving free daily toothbrushing to every 3 - 5-year old child attending nursery. Free distribution of toothpaste/toothbrush packs to every child every 3 months. Collection of routine monitoring data linked with national data sets from the previous survey regarding caries prevalence and risk factors.2.Monitor caries activity - net caries increment for initial, moderate, and extensive caries severity.
Study: NCT06293703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Biliopancreatic limb and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length in RYGB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Biliopancreatic limb and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length in RYGB
Study: NCT05421507

Intervention type: RADIATION
Intervention: Radioactive Iodine-125 Seeds Implantation
Description: Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.
Study: NCT04968808

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged in-hospital complete revascularization
Description: Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization
Description: Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Study: NCT05432856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating, nutrition education, and sedentary time reduction strategies
Description: 1. TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or fast by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week.~2. Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits.~3. Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life.
Study: NCT05320432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: A low-level electrical current through the skin activates the descending inhibitory systems in the central nervous system.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No current applied through pads.
Study: NCT05963373

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine analysis
Description: Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine analysis
Description: Diagnostic test
Study: NCT04931082

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT05116384

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: cryo energy via cryoballoon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: cryo energy via cryoballoon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: renal artery denervation
Description: RF energy delivery to multiple sites within each major renal artery
Study: NCT05961839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGR-2921
Description: SGR-2921 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGR-2921
Description: SGR-2921 will be administered orally.
Study: NCT05048459

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard surveillance
Description: Participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine surveillance (tele-surveillance)
Description: The tele-surveillance visit occurs annually after completion of therapy and consists of a phone call with or without video conferencing between the patient and the treatment team (physician, nurse, and/ or nurse practitioner). The use of video conferencing is strongly encouraged. Clinic visits, endoscopies, and imaging studies can be performed at the discretion of the treatment team for concerning patient symptoms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: EORTC QLQ-C30 and EORTC QLQ-HN43 at 12 and 24 months, FACE-Questionnaire Module, Telehealth Usability Questionnaire, Telehealth Usability Questionnaire, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction -Patient Satisfaction inventory

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: EORTC QLQ-C30 and EORTC QLQ-HN43 at 12 and 24 months, FACE-Questionnaire Module, Telehealth Usability Questionnaire, Telehealth Usability Questionnaire, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction -Patient Satisfaction inventory
Study: NCT04760613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: 600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical capsules containing placebo (taken daily by mouth)
Study: NCT05735327

Intervention type: DRUG
Intervention: No intervention
Description: As this is an observational study, no intervention will be administered.
Study: NCT04864210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Surgeons will perform an intercostal nerve block in the operating room under thoracoscopic guidance while the patient is asleep under anesthesia. This intervention (block) is one of the standards of care but the medication (liposomal bupivacaine) currently is not FDA approved for this type of block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: An anesthesiologist trained in regional anesthesia will perform a paravertebral block in the hospital's pain service unit. This intervention is standard of care and will use plain bupivacaine with epinephrine as the medication
Study: NCT06297083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut Oral Powder [PEANUT POWDER]
Description: Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut Oral Powder [PEANUT POWDER]
Description: Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Oral Powder [PEANUT POWDER]
Description: Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)
Description: Probiotic or placebo-probiotic given daily for 18 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)
Description: Probiotic or placebo-probiotic given daily for 18 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)
Description: Probiotic or placebo-probiotic given daily for 18 months
Study: NCT06434116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality
Description: The virtual reality headset is a device that simulates a realistic, three-dimensional environment, allowing the patient to be totally immersed, so that they feel as if they are really present in a virtual world. This environment can be combined with hypnotic verbal support.~Virtual reality will be achieved using a virtual reality headset (GAMIDA®, Pico G2 4K, France) and audio headphones with noise reduction (Bose® Quiet Comfort 35 II, France). A tablet (Samsung® Galaxy Tab A 2019, 4G / Lenovo M8, France) equipped with Healthy Mind software will enable patients to enjoy a 360° visual and auditory 3D experience via a Bluetooth connection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality
Description: The virtual reality headset is a device that simulates a realistic, three-dimensional environment, allowing the patient to be totally immersed, so that they feel as if they are really present in a virtual world. This environment can be combined with hypnotic verbal support.~Virtual reality will be achieved using a virtual reality headset (GAMIDA®, Pico G2 4K, France) and audio headphones with noise reduction (Bose® Quiet Comfort 35 II, France). A tablet (Samsung® Galaxy Tab A 2019, 4G / Lenovo M8, France) equipped with Healthy Mind software will enable patients to enjoy a 360° visual and auditory 3D experience via a Bluetooth connection.
Study: NCT05154773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kidney donation and transplant information made easy
Description: Same as arm description
Study: NCT06283355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasal Microbiota Transplant (NMT)
Description: nasal microbiota transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasal Microbiota Transplant (NMT)
Description: nasal microbiota transplant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sterile swab
Study: NCT05057637

Intervention type: DEVICE
Intervention: Optical coherence tomography measurements
Description: Optical coherence tomography measurements in femoropopliteal tract
Study: NCT06108414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose rivaroxaban
Description: Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose rivaroxaban
Description: Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
Study: NCT04929249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
Study: NCT06273774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT06291441

Intervention type: OTHER
Intervention: No intervention
Description: No intervention (observational study)
Study: NCT06591013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Transplantation of fresh fecal bacterial fluid into the ileocecum of patients with ulcerative colitis via the colonoscopic route

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Transplantation of fresh fecal bacterial fluid into the ileocecum of patients with ulcerative colitis via the colonoscopic route
Study: NCT06587685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-011Gel
Description: Twice daily for 52 weeks or 44 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Gel twice daily for 8 weeks
Study: NCT06588179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501+SHR-2005
Description: SHR-1501, instillation；SHR-2005, instillation
Study: NCT06598839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months